Balixafortide is a potent, selective antagonist of CXCR4 with a high affinity for human CXCR4 receptor shown to be used to chemosensitize tumor cells to eribulin through the disruption of the SDF-1- mediated prosurvival signaling in the tumor microenvironment in preclinical studies. The gene discussed is CXCL12; the disease is neoplasm.